Denali Therapeutics (DNLI)
(Delayed Data from NSDQ)
$13.44 USD
-0.39 (-2.82%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $13.43 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Denali Therapeutics Inc.'s return on equity, or ROE, is -35.90% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that DNLI has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
DNLI 13.44 -0.39(-2.82%)
Will DNLI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNLI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNLI
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review
DNLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report?
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Other News for DNLI
Denali Therapeutics' CMO Joins Royalty Pharma Board | DNLI Stock News
Royalty Pharma appoints Ho, Weatherman to board of directors
Denali noted no FDA panel meeting in call with William Blair
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License ...
Denali Therapeutics Inc (DNLI) Announces FDA Priority Review for Tividenofusp Alfa | DNLI stock news